{"id":"tp-39150","type":"article-newspaper","title":"Moderna, Merck Find 42% Lower Melanoma Recurrence-or-Death Risk","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/39150","datePublished":"2026-10-23T17:09:52.000Z","dateModified":"2026-10-23T17:09:52.000Z","language":"en","abstract":"Estimated two-year recurrence-free survival was 82.2% with the combination and 70.0% with Keytruda alone; overall-survival data remain immature.","section":"Business","references":[]}